The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon.
We have studied the pharmacokinetics of phenprocoumon with and without co-administration of frusemide and probenecid in two groups of 17 healthy volunteers. Frusemide 40 mg b.i.d. for 7 days did not interact with phenprocoumon to a significant extent. Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.h.ml-1, and a reduction in the fraction of the dose excreted by the kidneys. The data are consistent with inhibition of the glucuronidation of phenprocoumon by probenecid. Its accelerated elimination may be a consequence of the increased formation of hydroxylated metabolites.
Mönig
H
H
I. Medizinische Klinik, Christian-Albrechts-Universität, Kiel, FRG.
Böhm
M
M
Ohnhaus
E E
EE
Kirch
W
W
D000284:Administration, Oral; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005260:Female; D005665:Furosemide / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D008297:Male; D010644:Phenprocoumon / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D011339:Probenecid / Q000494:pharmacology*; D011517:Prothrombin Time
D005665:Furosemide; D011339:Probenecid; D010644:Phenprocoumon